Introduction: With progress in pancreatic surgery, a preservation of residual organ function has become more important. Pancreatic malignancies are occasionally accompanied by chronic pancreatitis (CP) and pancreatolithiasis (PL). Longitudinal pancreatojejunostomy (LPJ) is reportedly a useful method of surgical management in cases of CP with PL.
View Article and Find Full Text PDFBackground: The clinical impact of acute vasoreactivity testing with inhaled nitric oxide (NO testing) in severe pulmonary hypertension associated with lung disease (LD-PH) remains unknown.
Methods: We retrospectively reviewed 48 consecutive patients with severe LD-PH (73 ± 9 years; male: 81%) who underwent NO testing between 2014 and 2022. We conducted an exploratory analysis of the association between the response to NO testing and both the efficacy of pulmonary vasodilators and prognosis.
Background: Treatment options for patients with chronic thromboembolic hypertension (CTEPH) have increased over the past decade. However, it is unknown whether the outcomes of patients with CTEPH have changed as well.
Methods: This retrospective study analysed the data of 834 patients with CTEPH, categorised into early (April 1980-December 1999), middle (January 2000-September 2010), and current (October 2010-December 2023) eras.
Shape-persistent macrocycles with confined inner spaces have gained significant interest due to their unique properties and potential applications in gas/molecular recognition, nanoscale templates, and nanoelectronics. In this study, we present an efficient synthesis of macrocycles containing anthracene units through reversible boronic ester formation between 1,2-diols and boronic acids. These template-free macrocycles exhibited diverse internal cavities ranging from 11 Å to 20 Å and readily crystallized in solution and on solid substrates.
View Article and Find Full Text PDFIntroduction: Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, showed significantly longer progression-free survival (PFS) than crizotinib in the phase 3 CROWN trial (NCT03052608) in patients with previously untreated advanced ALK-positive non-small cell lung cancer (NSCLC). Efficacy was similar in the Asian subgroup. We present an updated subgroup analysis in Asian patients after 5 years of follow-up.
View Article and Find Full Text PDF